Publications

1. Calmodulin inhibition of human RyR2 channels requires phosphorylation of RyR2-S2808 or RyR2-S2814.
Walweel K, Gomez-Hurtado N, Rebbeck RT, Oo YW, Beard NA, Molenaar P, Dos Remedios C, van Helden DF, Cornea RL, Knollmann BC, Laver DR. 
Journal of Molecular and Cellular Cardiology. 2019.

ABSTRACT

2. Unnatural verticilide enantiomer inhibits type 2 ryandodine receptor-mediated calcium leak and is antiarrhythmic. 
Batiste SM, Blackwell DJ, Kim K, Kryshtal DO, Gomez-Hurtado N, Rebbeck RT, Cornea RL, Johnston JN, Knollman BC.
Proceedings of the National Academy of Sciences of the United States of America. 2019

ABSTRACT

3. Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells. 
Rebbeck RT, Essawy MM, Nitu FR, Grant BD, Gillispie GD, Thomas DD, Bers DM, Cornea RL.
Scientific Reports. 2018.

ABSTRACT

4. Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes. 
Ceholski DK, Turnbull IC, Kong CW, Koplev S, Mayourian J, Gorski PA, Stillitano F, Skodras AA, Nonnenmacher M, Cohen N, Björkegren JLM, Stroik DR, Cornea RL, Thomas DD, Li RA, Costa KD, Hajjar RJ.
Journal of Molecular and Cellular Cardiology. 2018.

ABSTRACT

5. High-throughput screens to discover small-molecule modulators of ryanodine receptor calcium release channels. 
Rebbeck RT, Essawy MM, Nitu FR, Grant BD, Gillispie GD, Thomas DD, Bers DM, Cornea RL.
SLAS Discovery: Advancing Life Sciences R & D. 2017.

ABSTRACT

6. CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. 
Uchinoumi H, Yang Y, Oda T, Li N, Alsina KM, Puglisi JL, Chen-Izu Y, Cornea RL, Wehrens XHT, Bers DM.
Journal of Molecular and Cellular Cardiology. 2016.

ABSTRACT

7. Novel CPVT-Associated calmodulin mutation in CALM3 (CALM3-A103V) activates arrhythmogenic Ca waves and sparks. 
Gomez-Hurtado N, Boczek NJ, Kryshtal DO, Johnson CN, Sun J, Nitu FR, Cornea RL, Chazin WJ, Calvert ML, Tester DJ, Ackerman MJ, Knollman BC.
Circulation. Arrhythmia and Electrophysiology. 2016

ABSTRACT

8. S100A1 protein does not compete with calmodulin for ryanodine receptor binding but structurally alters the ryanodine receptor/calmodulin complex. 
Rebbeck RT, Nitu FR, Rohde D, Most P, Bers DM, Thomas DD, Cornea RL.
The Journal of Biological Chemistry. 2016.

ABSTRACT

9. Crystal structures of ryanodine receptor SPRY1 and tandem-repeat domains reveal a critical FKBP12 binding determinant. 
Yuchi Z, Yuen SM, Lau K, Underhill AQ, Cornea RL, Fessenden JD, Van Petegem F.
Nature Communications. 2015.

ABSTRACT

10. Oxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and pathologically alter, RyR structure and calmodulin affinity.
Oda T, Yang Y, Uchinoumi H, Thomas DD, Chen-Izu Y, Kato T, Yamamoto T, Yano M, Cornea RL, Bers DM.
Journal of Molecular and Cellular Cardiology. 2015.

ABSTRACT

Patents

U.S. patent no. 8431356:  Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium ATPase and phospholamban. Inventors: David D. Thomas, Razvan L. Cornea, and Krisztina M. Zsebo. Issued October 2012. Assigned to University of Minnesota, with exclusive commercial license to Photonic Pharma, L.L.C.

U.S. patent no. 10281476: FRET-based high-throughput screening methods to discover modulators of RyR calcium channels Inventors: Razvan L. Cornea,  Donald M. Bers, David D. Thomas, Gregory D. Gillispie. Issued May 2019. 

U.S. patent application no. 14/598,707: High-throughput, high-precision methods for detecting protein structural changes in living cells Inventors: David D. Thomas, Simon J. Gruber, Razvan L. Cornea, Gregory D. Gillispie, Seth L. Robia. Filed Jan. 16, 2015.